Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease

Neuroscience

Volumn 299, Issue , 2015, Pages 156-174

  Sconce, M D ^a   Churchill, M J ^a   Greene, R E ^a   Meshul, C K ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Exercise; Glutamate transporters; Motor behavior; MPTP; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; TRANSCRIPTION FACTOR NFAT3; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; SLC17A7 PROTEIN, MOUSE; SLC18A2 PROTEIN, MOUSE; SLC1A1 PROTEIN, MOUSE; SLC1A2 PROTEIN, MOUSE; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; BRAIN REGION; CELL GROWTH; CELL LOSS; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; DORSOLATERAL STRIATUM; IMMUNOREACTIVITY; KINESIOTHERAPY; MACROGLIA; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RUNNING; SUBSTANTIA NIGRA; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; COMPLICATION; CONVALESCENCE; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; GAIT; HAND STRENGTH; INFLAMMATION; METABOLISM; PARKINSONISM; PATHOPHYSIOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXCITATORY AMINO ACID TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 3; GAIT; HAND STRENGTH; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; NEURONS; PARKINSONIAN DISORDERS; PHYSICAL CONDITIONING, ANIMAL; RECOVERY OF FUNCTION; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84929317325     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.04.069     Document Type: Article

References (105)

1. Abercrombie E.D., Bonatz A.E., Zigmond M.J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990, 525(1):36-44.
2. Adlard P.A., Perreau V.M., Cotman C.W. The exercise-induced expression of BDNF within the hippocampus varies across life-span. Neurobiol Aging 2005, 26(4):511-520.
3. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989, 12(10):366-375.
4. Al-Jarrah M., Pothakos K., Novikova L., Smirnova I.V., Kurz M.J., Stehno-Bittel L., Lau Y.S. Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration. Neuroscience 2007, 149(1):28-37.
5. Amende I., Kale A., McCue S., Glazier S., Morgan J.P., Hampton T.G. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J Neuroeng Rehabil 2005, 2:20.
6. Baatile J., Langbein W.E., Weaver F., Maloney C., Jost M.B. Effect of exercise on perceived quality of life of individuals with Parkinson's disease. J Rehabil Res Dev 2000, 37(5):529-534.
7. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F.1. Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20(4):415-455.
8. Bezard E., Gross C.E., Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003, 26(4):215-221.
9. Bilowit D.S. Establishing physical objectives in the rehabilitation of patients with Parkinson's disease; gymnasium activities. Phys Ther Rev 1956, 36(3):176.
10. Black J.E., Isaacs K.R., Anderson B.J., Alcantara A.A., Greenough W.T. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. Proc Natl Acad Sci 1990, 87(14):5568-5572.
11. Blandini F., Porter R.H., Greenamyre J.T. Glutamate and Parkinson's disease. Mol Neurobiol 1996, 12(1):73-94.
12. Blandini F., Armentero M.T. Animal models of Parkinson's disease. FEBS J 2012, 279(7):1156-1166.
13. Carvalho A.L., Caldeira M.V., Santos S.D., Duarte C.B. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008, 153(Suppl. 1):S310-S324.
14. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003, 4(4):299-309.
15. Checkoway H., Powers K., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002, 155(8):732-738.
16. Chen H., O'Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008, 167(1):90-95.
17. Chen Z., Trapp B.D. Microglia and neuroprotection. J Neurochem 2015, 10.1111/jnc.13062.
18. Cheramy A., Leviel V., Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature 1981, 289(5798):537-543.
19. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988, 1(8):623-634.
20. Chotibut T., Apple D.M., Jefferis R., Salvatore M.F. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake. PLoS One 2012, 7(12):e52322.
21. Colton C.A. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 2009, 4(4):399-418.
22. Cotman C.W., Berchtold N.C., Christie L.A. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 2007, 30(9):464-472.
23. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262(5134):689-695.
24. Chung Y.C., Kim S.R., Jin B.K. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010, 185(2):1230-1237.
25. Cobb M.H. MAP kinase pathways. Prog Biophys Mol Biol 1999, 71(3-4):479-500.
26. Cotman C.W., Berchtold N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002, 25(6):295-301.
27. Crabtree G.R., Olson E.N. NFAT signaling: choreographing the social lives of cells. Cell 2002, 109:S67-S79.
28. Day M., Wang Z., Ding J., An X., Ingham C.A., Shering A.F., Surmeier D.J. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 2006, 9(2):251-259.
29. Ehninger D., Kempermann G. Regional effects of wheel running and environmental enrichment on cell genesis and microglia proliferation in the adult murine neocortex. Cerebral Cortex 2003, 13(8):845-851.
30. Fellows S.J., Noth J. Grip force abnormalities in de novo Parkinson's disease. Mov Disord 2004, 19(5):560-565.
31. Fisher B.E., Petzinger G.M., Nixon K., Hogg E., Bremmer S., Meshul C.K., Jakowec M.W. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1, 2, 3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 2004, 77(3):378-390.
32. Fisher B.E., Wu A.D., Salem G.J., Song J., Lin C.H.J., Yip J., Petzinger G. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. Arch Phys Med Rehabil 2008, 89(7):1221-1229.
33. Geffen L.B., Jessell T.M., Cuello A.C., Iversen L.L. Release of dopamine from dendrites in rat substantia nigra. Nature 1976, 258-260.
34. Gerecke K.M., Jiao Y., Pani A., Pagala V., Smeyne R.J. Exercise protects against MPTP-induced neurotoxicity in mice. Brain Res 2010, 1341:72-83.
35. Goldberg N.R., Haack A.K., Lim N.S., Janson O.K., Meshul C.K. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2011, 180:256-271.
36. Goldberg N.R., Hampton T., McCue S., Kale A., Meshul C.K. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning. J Neurosci Res 2011, 89(10):1698-1706.
37. Goldberg N.R., Fields V., Pflibsen L., Salvatore M.F., Meshul C.K. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Neurobiol Dis 2012, 45(3):1051-1067.
38. Gorton L.M., Vuckovic M.G., Vertelkina N., Petzinger G.M., Jakowec M.W., Wood R.I. Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav Brain Res 2010, 213(2):253-262.
39. Greenfield S.A. The significance of dendritic release of transmitter and protein in the substantia nigra. Neurochem Int 1985, 7(6):887-901.
40. Grewal S.S., York R.D., Stork P.J. Extracellular-signal-regulated kinase signalling in neurons. Curr Opin Neurobiol 1999, 9(5):544-553.
41. Guillin O., Diaz J., Carroll P., Griffon N., Schwartz J.C., Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001, 411(6833):86-89.
42. Hattori S., Naoi M., Nishino H. Striatal dopamine turnover during treadmill running in the rat: relation to the speed of running. Brain Res Bull 1994, 35(1):41-49.
43. Hatzipetros T., Yamamoto B.K. Dopaminergic and GABAergic modulation of glutamate release from rat subthalamic nucleus efferents to the substantia nigra. Brain Res 2006, 1076(1):60-67.
44. Holmer H.K., Keyghobadi M., Moore C., Meshul C.K. L-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2005, 136(1):333-341.
45. Howells F.M., Russell V.A., Mabandla M.V., Kellaway L.A. Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease. Behav Brain Res 2005, 165(2):210-220.
46. Iversen L.L. Role of transmitter uptake mechanisms in synaptic neurotransmission. Brit J Pharmacol 1971, 41(4):571-591.
47. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008, 79(4):368-376.
48. Kale A., Amende I., Meyer G.P., Crabbe J.C., Hampton T.G. Ethanol's effects on gait dynamics in mice investigated by ventral plane videography. Alcohol Clin Exp Res 2004, 28(12):1839-1848.
49. Kaneko T., Fujiyama F., Hioki H. Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain. J Comp Neurol 2002, 444(1):39-62.
50. Klockgether T., Turski L., Honoré T., Zhang Z., Gash D.M., Kurlan R., Greenamyre J.T. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991, 30(5):717-723.
51. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., Bartus R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136(8):2419-2431.
52. Lau Y.S., Patki G., Das-Panja K., Le W.D., Ahmad S.O. Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration. Eur J Neurosci 2011, 33(7):1264-1274.
53. Li Li-Bin, Chen Nianhang, Ramamoorthy Sammanda, Chi Limen, Cui Xiao-Nan, Wang Lijuan C., Reith Maarten E.A. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem 2004, 279(20):21012-21020.
54. Lis H., Sharon N. Lectins: carbohydrate-specific proteins that mediate cellular recognition. Chem Rev 1998, 98(2):637-674.
55. Liu B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J 2006, 8(3):E606-E621.
56. Luo J., Sun L., Lin X., Liu G., Yu J., Parisiadou L., Cai H. A calcineurin and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons. Hum Mol Genet 2014, ddu377.
57. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005, 5:472-484.
58. Maesawa S., Kaneoke Y., Kajita Y., Usui N., Misawa N., Nakayama A., Yoshida J. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg 2004, 100(4):679-687.
59. Maragakis N.J., Rothstein J.D. Glutamate transporters: animal models to neurologic disease. Neurobiol Dis 2004, 15(3):461-473.
60. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2006, 2(12):679-689.
61. Massie A., Goursaud S., Schallier A., Vermoesen K., Meshul C.K., Hermans E., Michotte Y. Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats. Neurochem Int 2010, 57(5):572-578.
62. Meeusen R., Smolders I., Sarre S., De Meirleir K., Keizer H., Serneels M., Michotte Y. Endurance training effects on neurotransmitter release in rat striatum: an in vivo microdialysis study. Acta Physiol Scand 1997, 159(4):335-341.
63. Meredith G.E., Totterdell S., Potashkin J.A., Surmeier D.J. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 2008, 14(Suppl. 2):S112-S115.
64. Meredith G.E., Totterdell S., Beales M., Meshul C.K. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol 2009, 219(1):334-340.
65. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 1999, 88(1):1-16.
66. Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 2009, 10(12):850-860.
67. Mirza B., Hadberg H., Thomsen P., Moos T. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 1999, 95(2):425-432.
68. Moroz I.A., Pecina S., Schallert T., Stewart J. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine. Exp Neurol 2004, 189(1):78-93.
69. Nowak D.A., Hermsdörfer J. Predictive and reactive control of grasping forces: on the role of the basal ganglia and sensory feedback. Exp Brain Res 2006, 173(4):650-660.
70. O'dell S.J., Gross N.B., Fricks A.N., Casiano B.D., Nguyen T.B., Marshall J.F. Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection. Neuroscience 2007, 144(3):1141-1151.
71. Oliff H.S., Berchtold N.C., Isackson P., Cotman C.W. Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Mol Brain Res 1998, 61(1):147-153.
72. Paul G., Meissner W., Rein S., Harnack D., Winter C., Hosmann K., Kupsch A. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 2004, 185(2):272-280.
73. Politis M., Wu K., Molloy S., Bain P.G., Chaudhuri K., Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010, 25(11):1646-1651.
74. Pothakos K., Kurz M.J., Lau Y.S. Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. BMC Neurosci 2009, 10(1):6.
75. Petzinger G.M., Walsh J.P., Akopian G., Hogg E., Abernathy A., Arevalo P., Jakowec M.W. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci 2007, 27(20):5291-5300.
76. Petzinger G.M., Fisher B.E., Van Leeuwen J.E., Vukovic M., Akopian G., Meshul C.K., Jakowec M.W. Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease. Mov Disord 2010, 25(S1):S141-S145.
77. Petzinger G.M., Fisher B.E., McEwen S., Beeler J.A., Walsh J.P., Jakowec M.W. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. Lancet Neurol 2013, 12(7):716-726.
78. Plaitakis A., Shashidharan P. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J Neurol 2000, 247(2):II25-II35.
79. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003, 60(8):1234-1240.
80. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm 1976, 38(3-4):277-301.
81. Robinson T.E., Castan eda E., Whishaw I.Q. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. Can J Psychol 1990, 44(2):253-275.
82. Robinson S., Freeman P., Moore C., Touchon J.C., Krentz L., Meshul C.K. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp Neurol 2003, 180(1):74-87.
83. Ross G.W., Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001, 18(11):797-806.
84. Rothstein J.D., Martin L., Levey A.I., Dykes-Hoberg M., Jin L., Wu D., Kuncl R.W. Localization of neuronal and glial glutamate transporters. Neuron 1994, 13(3):713-725.
85. Russo-Neustadt A., Beard R.C., Cotman C.W. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999, 21(5):679-682.
86. Sconce M.D., Churchill M.J., Moore C., Meshul C.K. Intervention with 7,8-dihydroxyflavone blocks further striatal terminal loss and restores motor deficits in a progressive mouse model of Parkinson's disease. Neuroscience 2015, 290:454-471.
87. Shashidharan P., Huntley G.W., Murray J.M., Buku A., Moran T., Walsh M.J., Plaitakis A. Immunohistochemical localization of the neuron-specific glutamate transporter EAAC1 (EAAT3) in rat brain and spinal cord revealed by a novel monoclonal antibody. Brain Res 1997, 773(1):139-148.
88. Skaper S.D. The neurotrophin family of neurotrophic factors: an overview. Methods Mol Biol 2012, 846:1-12.
89. Smith B.A., Goldberg N.R., Meshul C.K. Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse. Brain Res 2011, 1386:70-80.
90. Snyder G.L., Keller R.W., Zigmond M.J. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J Pharmacol Exp Ther 1990, 253(2):867-876.
91. Szekely B.C., Kosanovich N.N., Sheppard W. Adjunctive treatment in Parkinson's disease: physical therapy and comprehensive group therapy. Rehabil Lit 1982, 43:72-76.
92. Teismann P., Schulz J.B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 2004, 318:149-161.
93. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med 2011, 1(1):a009316.
94. Tillerson J.L., Caudle W.M., Reveron M.E., Miller G.W. Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease. Neuroscience 2003, 119(3):899-911.
95. Toole T., Hirsch M.A., Forkink A., Lehman D.A., Maitland C.G. The effects of a balance and strength training program on equilibrium in Parkinsonism: a preliminary study. NeuroRehabilitation 2000, 14(3):165-174.
96. Touchon J.C., Moore C., Frederickson J., Meshul C.K. Lesion subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations. Synapse 2004, 51(4):287-298.
97. 18F]fallypride. Mov Disord. 2010, 25(16):2777-2784.
98. Walker R.H., Koch R.J., Sweeney J.E., Moore C., Meshul C.K. Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum. Neuroreport 2009, 20(8):770-775.
99. Wilson W.M., Marsden C.A. Extracellular dopamine in the nucleus accumbens of the rat during treadmill running. Acta Physiol Scand 1995, 155(4):465-466.
100. Xu S.G., Prasad C., Smith D.E. Neurons exhibiting dopamine d 2 receptor immunoreactivity in the substantia nigra of the mutant weaver mouse. Neuroscience 1999, 89(1):191-207.
101. Yoon M.C., Shin M.S., Kim T.S., Kim B.K., Ko I.G., Sung Y.H., Kim C.J. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats. Neurosci Lett 2007, 423(1):12-17.
102. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984, 41(8):856-861.
103. Zigmond M.J., Stricker E.M. Parkinson's disease: studies with an animal model. Life Sci 1984, 35(1):5-18.
104. Zigmond M.J., Berger T.W., Grace A.A., Stricker E.M. Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol Chem Neuropathol 1989, 10(3):185-200.
105. Zigmond M.J., Hastings T.G., Abercrombie E.D. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease. Ann N Y Acad Sci 1992, 648:71-86.